Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial

Basit Öğe Kaydı
dc.authorid0000-0002-5209-8076en_US
dc.contributor.authorDogan, Nurettin Ozgur
dc.contributor.authorPekdemir, Murat
dc.contributor.authorYilmaz, Serkan
dc.contributor.authorYaka, Elif
dc.contributor.authorKaradas, Adnan
dc.contributor.authorDurmus, Ugur
dc.contributor.authorAvcu, Nazire
dc.contributor.authorKockan, Esra
dc.date.accessioned2024-07-12T21:44:18Z
dc.date.available2024-07-12T21:44:18Z
dc.date.issued2019en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractObjectives The present study aimed to evaluate the efficacy and safety of intravenous metoclopramide for acute migraine treatment. Materials and methods A double-blind, randomized, parallel-group, placebo-controlled trial was carried out in an academic emergency department. After the patients were assessed for eligibility via the International Headache Society criteria for migraines, they were randomized into 10 mg intravenous metoclopramide and normal saline groups. The headache intensity was evaluated using an 11-point numeric rating scale (NRS) score. The primary outcome measure was determined as the median between-group change in the score at the 30th minute. The secondary outcome measures were rescue medication needs, adverse events, and emergency department (ED) revisits after discharge. Results A total of 148 patients were randomized into two equal groups with similar baseline characteristics, including the baseline NRS scores (8 points). The median reduction in the NRS scores at the 30th minute was 4 [interquartile range (IQR): 2-6)] in the metoclopramide group and 3 (IQR: 1-4) in the normal saline group [median difference: -1.0, 95% confidence interval (CI): -2.1 to 0.1]. No serious adverse events were observed, and the rescue medication needs were similar in both groups. Conclusion No difference was found between intravenous metoclopramide and placebo regarding efficacy and safety in patients with acute migraines.en_US
dc.identifier.doi10.1111/ane.13063
dc.identifier.endpage339en_US
dc.identifier.issn0001-6314
dc.identifier.issn1600-0404
dc.identifier.issue4en_US
dc.identifier.pmid30629285en_US
dc.identifier.scopus2-s2.0-85060765612en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage334en_US
dc.identifier.urihttps://dx.doi.org/10.1111/ane.13063
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7709
dc.identifier.volume139en_US
dc.identifier.wosWOS:000460960400002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofACTA NEUROLOGICA SCANDINAVICAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00048
dc.subjectemergency department (MeSH Database)en_US
dc.subjectheadacheen_US
dc.subjectmetoclopramideen_US
dc.subjectmigraineen_US
dc.titleIntravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trialen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu